Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.9, Iss.1, 2008-01, pp. : 1-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Warfarin Pharmacogenetics: Economic Considerations

By Hughes Dyfrig A.

PharmacoEconomics, Vol. 25, Iss. 11, 2007-01 ,pp. : 899-902

Adis International

Access to resources Recommend Favorite

The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation

By Picard Nicolas Marquet Pierre

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 6, 2011-06 ,pp. : 731-743

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenomics and pharmacogenetics of neurodegenerative diseases: towards new targets

By Amouyel Philippe

Pharmacogenomics, Vol. 3, Iss. 1, 2002-01 ,pp. : 1-3

Future Medicine

Access to resources Recommend Favorite

Pharmacogenetics Research Network and Knowledge Base: 1st Annual Scientific Meeting

By Davis Alison Long Rochelle

Pharmacogenomics, Vol. 2, Iss. 3, 2001-08 ,pp. : 285-289

Future Medicine

Access to resources Recommend Favorite

Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine

By Umićević Mirkov Maša Coenen Marieke JH

Pharmacogenomics, Vol. 14, Iss. 4, 2013-03 ,pp. : 425-444

Future Medicine

Access to resources Recommend Favorite